Clues for drugging the 'undruggable'

(Friedrich Miescher Institute) Nicolas Thom ä 's group at the Friedrich Miescher Institute for Biomedical Research (FMI) has joined forces with the group of Benjamin Ebert at Harvard's Broad Institute to show how thalidomide analogs mediate degradation of many more proteins than previously anticipated. These proteins -- zinc finger transcription factors -- play a role in cancer and developmental diseases but are difficult drug targets. The new study, published in Science, suggests that thalidomide analogs can be rationally designed to target this challenging class of proteins.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news